Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board

[admin]

NEW ORLEANS and LONDON, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced the appointment of industry veteran Tunde Otulana, M.D., to its Board of Directors. Dr. Otulana brings more than 25 years of leadership, clinical development and regulatory strategy experience in the life sciences indu